<SEC-DOCUMENT>0001279569-20-000129.txt : 20200203
<SEC-HEADER>0001279569-20-000129.hdr.sgml : 20200203
<ACCEPTANCE-DATETIME>20200203081614
ACCESSION NUMBER:		0001279569-20-000129
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200203
FILED AS OF DATE:		20200203
DATE AS OF CHANGE:		20200203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AURORA CANNABIS INC
		CENTRAL INDEX KEY:			0001683541
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38691
		FILM NUMBER:		20567037

	BUSINESS ADDRESS:	
		STREET 1:		500 - 10355 JASPER AVENUE
		CITY:			EDMONTON
		STATE:			A0
		ZIP:			T5J 1Y6
		BUSINESS PHONE:		604-362-5207

	MAIL ADDRESS:	
		STREET 1:		900 - 510 SEYMOUR STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6B 1V5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>aurora_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT><BR>
<FONT STYLE="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
<B>Washington, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B>RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">For the month of <B>February 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Commission File No. <B>001-38691</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>AURORA
CANNABIS INC.</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 24pt"></FONT><BR>
<FONT STYLE="font-size: 10pt">(Translation of registrant's name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>500 - 10355 Jasper Avenue</B><BR>
<B>Edmonton, Alberta, T5J 1Y6, Canada</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B></B><BR>
(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B> Form
40-F&nbsp;&nbsp;&#9746;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) &nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) &nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>SUBMITTED HEREWITH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font: 12pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibits</B></FONT></TD>
    <TD STYLE="width: 2%"></TD>
    <TD STYLE="width: 90%; font: 12pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; text-align: left; text-transform: uppercase"><A HREF="ex991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">News
Release dated   February 3, 2020</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><A HREF="ex991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></A></TD>
    <TD></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm"></A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>AURORA CANNABIS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">/s/ <I>Glen Ibbott</I></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"><I></I><BR>
Glen Ibbott<BR>
Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Date:  February 3, 2020</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED FEBRUARY 3, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Aurora Cannabis Receives EU GMP Certification
for its Aurora River Facility</P>

<UL STYLE="list-style-type: disc">

<LI STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B><I>Achievement increases total production capacity available
to serve international medical markets by 230%</I></B></LI>

<LI STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B><I>Brings Aurora's total number of EU GMP certified
Canadian production facilities to 3</I></B></LI>

<LI STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B><I>Pharmacies in Germany have been instructed to resume
sales of Aurora's suite of medical cannabis following temporary pause </I></B></LI>

</UL>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">NYSE | TSX : ACB&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">EDMONTON, Feb. 3, 2020 /CNW/ -&nbsp;Aurora
Cannabis Inc. (&quot;Aurora&quot; or the &quot;Company&quot;) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis
worldwide, announced today its Aurora River production facility, located in Bradford, Ontario, has received European Union Good
Manufacturing Practice (&quot;EU GMP&quot;) certification. EU GMP certification is granted to companies whose production facilities
demonstrate a high degree of quality and consistency in their manufacturing procedures and is a requirement for the export of medical
cannabis products into most European markets.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In addition, Aurora is pleased to announce
it has received all necessary approvals from local regulators in Germany for sales of its medical cannabis products, following
a temporary sales suspension on certain products in December 2019. Aurora will fulfill existing sales orders from inventory currently
held in Germany, ensuring local patients will have immediate access to medicine from their preferred pharmacy.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;Aurora is leading the development of
medical markets across Europe and around the world,&quot; said Terry Booth, CEO of Aurora. &quot;The EU GMP certification of our
River facility further validates our strategy focused on purpose-built facilities, designed and constructed exclusively for the
production of high-quality, pharmaceutical grade cannabis. I congratulate our team on successfully working with regulators and
licensing bodies to ensure Aurora's facilities and products are in accordance with local and international standards that will
allow for greater access to the highest quality medical cannabis products to patients who need them.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Designed for large scale, high quality production,
Aurora River has a cultivation capacity of 28,000 kg per year across its 17 fully-planted, independently climate-controlled grow
rooms. The EU GMP certification of Aurora River enables the Company to allocate both a greater quantity of dried and extracted
product to international markets as well as introduce new products grown and produced in the facility. To date, Aurora has received
EU GMP certification for 3 of its 10 Canadian production facilities. Aurora River joins Aurora Mountain, located in Mountain View
County, Alberta with a production capacity of 4,800 kg a year, and Aurora Ridge located in Markham, Ontario with a production capacity
of 7,000 kg a year, in achieving this important certification.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Aurora</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Headquartered in Edmonton, Alberta, Canada
with sales and operations in 25 countries across five continents, Aurora is one of the world's largest and leading cannabis companies.
Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering
and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development,
home cultivation, wholesale and retail distribution.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Highly differentiated from its peers, Aurora
has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate
leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale
production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed
to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of
Aurora's facilities is built to meet European Union Good Manufacturing Practices (&quot;EU GMP&quot;) standards. Certification
has been granted to Aurora's first production facility in Mountain View County, Aurora Ridge, Aurora River, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In addition to the Company's rapid organic
growth and strong execution on strategic M&amp;A, which to date includes 17 wholly owned subsidiary companies &ndash; MedReleaf,
CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco &ndash; Aurora
is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established
strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX:
CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc.
(TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private).</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Aurora's Common Shares trade on the TSX and
NYSE under the symbol &quot;ACB&quot;, and is a constituent of the S&amp;P/TSX Composite Index.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">For more information about Aurora, please visit
our investor website, investor.auroramj.com.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Terry Booth, CEO<BR>
Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward Looking Statements </B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">This news release includes statements containing
certain &quot;forward-looking information&quot; within the meaning of applicable securities law (&quot;forward-looking statements&quot;).
Forward-looking statements are frequently characterized by words such as &quot;plan&quot;, &quot;continue&quot;, &quot;expect&quot;,
&quot;project&quot;, &quot;intend&quot;, &quot;believe&quot;, &quot;anticipate&quot;, &quot;estimate&quot;, &quot;may&quot;, &quot;will&quot;,
&quot;potential&quot;, &quot;proposed&quot; and other similar words, or statements that certain events or conditions &quot;may&quot;
or &quot;will&quot; occur. These forward-looking statements are only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking
statements are based on the opinions, estimates and assumptions of management in light of management's experience and perception
of historical trends, current conditions and expected developments at the date the statements are made, such as current and future
market conditions, the current and future regulatory environment and future approvals and permits. Forward-looking statements are
subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances
could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially
from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and
regulations, product demand, changes in prices of required commodities, competition and other risks, uncertainties and factors
set out under the heading &quot;Risk Factors&quot; in the Company's annual information form dated September 10, 2019 (the &quot;AIF&quot;)
and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. The Company
cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could
also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating
the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as expressly required by applicable securities laws.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-receives-eu-gmp-certification-for-its-aurora-river-facility-300997549.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/February2020/03/c8601.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001683541</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>For Media: Laura Gallant, +1.437.992.8429,
laura.gallant@auroramj.com; For Investors: Rob Kelly, +1.647.331.7228, rob.kelly@auroramj.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 07:00e 03-FEB-20</P>



<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>



<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>



<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>



<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>



<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  < )4# 2(  A$! Q$!_\0
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M[5;'PO8:7H%[H]II$TDD<-U-YC-N96VK_P!\U^@Y;DT;T9RI_P"+FY>7X?\
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MJ#XG?M5?"CX+^(AH/C/QIIV@:NT2SBUN=V[RV^ZWRK7YC^)?^4RUE_V-%O\
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BPM8^.-#O/#WB72XVT^>VU),2.D>!&X]BI _"BO=J* /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
